Enhancement of cisplatin-mediated apoptosis in ovarian cancer cells through potentiating G2/M arrest and p21 upregulation by combinatorial epigallocatechin gallate and sulforaphane

Journal of Oncology

Volumn , Issue , 2013, Pages

  Chen, Huaping ^a   Landen, Charles N ^a   Li, Yuanyuan ^a   Alvarez, Ronald D ^a   Tollefsbol, Trygve O ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIGALLOCATECHIN GALLATE; PROTEIN P21; PROTEIN P27; SULFORAPHANE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MTT ASSAY; OVARIAN CANCER CELL LINE; OVARY CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; UPREGULATION; WESTERN BLOTTING;

EID: 84888248239     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2013/872957     Document Type: Article

References (30)

1. Agarwal R., Kaye S. B., Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nature Reviews Cancer 2003 3 7 502 516 2-s2.0-0043240182
2. Chen H., Hardy T. M., Tollefsbol T. O., Epigenomics of ovarian cancer and its chemoprevention. Frontiers in Genetics 2011 2, article 67
3. Wendel H. G., De Stanchina E., Fridman J. S., Malina A., Ray S., Kogan S., Cordon-Cardo C., Pelletier J., Lowe S. W., Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004 428 6980 332 337 2-s2.0-1642586272 10.1038/nature02369
4. Zhang M., Binns C. W., Lee A. H., Tea consumption and ovarian cancer risk: a case-control study in China. Cancer Epidemiology Biomarkers and Prevention 2002 11 8 713 718 2-s2.0-0036323603
5. Yoon J. S., Kristal A. R., Wicklund K. G., Cushing-Haugen K. L., Rossing M. A., Coffee, tea, colas, and risk of epithelial ovarian cancer. Cancer Epidemiology Biomarkers and Prevention 2008 17 3 712 716 2-s2.0-41549114650 10.1158/1055-9965.EPI-07-2511
6. Nagle C. M., Olsen C. M., Bain C. J., Whiteman D. C., Green A. C., Webb P. M., Tea consumption and risk of ovarian cancer. Cancer Causes and Control 2010 21 9 1485 1491 2-s2.0-77956974314 10.1007/s10552-010-9577-7
7. van Poppel G., Verhoeven D. T. H., Verhagen H., Goldbohm R. A., Brassica vegetables and cancer prevention: epidemiology and mechanisms. Advances in Experimental Medicine and Biology 1999 472 159 168 2-s2.0-0034468543
8. Mittal A., Pate M. S., Wylie R. C., Tollefsbol T. O., Katiyar S. K., EGCG down-regulates telomerase in human breast carcinoma MCF-7 cells, leading to suppression of cell viability and induction of apoptosis. International Journal of Oncology 2004 24 3 703 710 2-s2.0-5444270872
9. Spinella F., Rosanò L., Di Castro V., Decandia S., Albini A., Nicotra M. R., Natali P. G., Bagnato A., Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. Molecular Cancer Therapeutics 2006 5 6 1483 1492 2-s2.0-33746038556 10.1158/1535-7163.MCT-06-0053
10. Berletch J. B., Liu C., Love W. K., Andrews L. G., Katiyar S. K., Tollefsbol T. O., Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG. Journal of Cellular Biochemistry 2008 103 2 509 519 2-s2.0-38649100332 10.1002/jcb.21417
11. Chen H., Li Y., Tollefsbol T. O., Strategies targeting telomerase inhibition. Molecular Biotechnology 2009 41 2 194 199 2-s2.0-67749097761 10.1007/s12033-008-9117-9
12. Fang M. Z., Wang Y., Ai N., Hou Z., Sun Y., Lu H., Welsh W., Yang C. S., Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Research 2003 63 22 7563 7570 2-s2.0-0345275879
13. Thimmulappa R. K., Mai K. H., Srisuma S., Kensler T. W., Yamamoto M., Biswal S., Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Research 2002 62 18 5196 5203 2-s2.0-0037106099
14. Langouët S., Furge L. L., Kerriguy N., Nakamura K., Guillouzo A., Guengerich F. P., Inhibition of human cytochrome P450 enzymes by 1,2-dithiole-3-thione, oltipraz and its derivatives, and sulforaphane. Chemical Research in Toxicology 2000 13 4 245 252 2-s2.0-0034014663 10.1021/tx990189w
15. Gamet-Payrastre L., Li P., Lumeau S., Cassar G., Dupont M. A., Chevolleau S., Gasc N., Tulliez J., Tercé F., Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Research 2000 60 5 1426 1433 2-s2.0-0034162822
16. Bertl E., Bartsch H., Gerhäuser C., Inhibition of angiogenesis and endothelial cell functions are novel sulforaphane-mediated mechanisms in chemoprevention. Molecular Cancer Therapeutics 2006 5 3 575 585 2-s2.0-33645472584 10.1158/1535-7163.MCT-05-0324
17. Heiss E., Herhaus C., Klimo K., Bartsch H., Gerhäuser C., Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. The Journal of Biological Chemistry 2001 276 34 32008 32015 2-s2.0-0035943597 10.1074/jbc.M104794200
18. Myzak M. C., Karplus P. A., Chung F. L., Dashwood R. H., A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Research 2004 64 16 5767 5774 2-s2.0-4143130097 10.1158/0008-5472.CAN- 04-1326
19. Huh S. W., Bae S. M., Kim Y. W., Lee J. M., Namkoong S. E., Lee I. P., Kim S. H., Kim C. K., Ahn W. S., Anticancer effects of (-)-epigallocatechin-3- gallate on ovarian carcinoma cell lines. Gynecologic Oncology 2004 94 3 760 768 2-s2.0-4444307804 10.1016/j.ygyno.2004.05.031
20. Mi R. R., Ni H., MDM2 sensitizes a human ovarian cancer cell line. Gynecologic Oncology 2003 90 2 238 244 2-s2.0-0041622952 10.1016/S0090-8258(03) 00282-8
21. Li X., Wang G., Zhao J., Ding H., Cunningham C., Chen F., Flynn D. C., Reed E., Li Q. Q., Antiproliferative effect of β -elemene in chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2-M phase. Cellular and Molecular Life Sciences 2005 62 7-8 894 904 2-s2.0-18544381215 10.1007/s00018-005-5027-1
22. Mangala L. S., Zuzel V., Schmandt R., Leshane E. S., Halder J. B., Armaiz-Pena G. N., Spannuth W. A., Tanaka T., Shahzad M. M. K., Lin Y. G., Nick A. M., Danes C. G., Lee J. W., Jennings N. B., Vivas-Mejia P. E., Wolf J. K., Coleman R. L., Siddik Z. H., Lopez-Berestein G., Lutsenko S., Sood A. K., Therapeutic targeting of ATP7B in ovarian carcinoma. Clinical Cancer Research 2009 15 11 3770 3780 2-s2.0-66649118310 10.1158/1078-0432.CCR-08-2306
23. Spannuth W. A., Mangala L. S., Stone R. L., Carroll A. R., Nishimura M., Shahzad M. M. K., Lee S. J., Moreno-Smith M., Nick A. M., Liu R., Jennings N. B., Lin Y. G., Merritt W. M., Coleman R. L., Vivas-Mejia P. E., Zhou Y., Krasnoperov V., Lopez-Berestein G., Gill P. S., Sood A. K., Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Molecular Cancer Therapeutics 2010 9 8 2377 2388 2-s2.0-77955484001 10.1158/1535-7163.MCT-10-0200
24. Katano K., Kondo A., Safaei R., Holzer A., Samimi G., Mishima M., Kuo Y. M., Rochdi M., Howell S. B., Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Research 2002 62 22 6559 6565 2-s2.0-0037112421
25. Fang M. Z., Wang Y., Ai N., Hou Z., Sun Y., Lu H., Welsh W., Yang C. S., Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Research 2003 63 22 7563 7570 2-s2.0-0345275879
26. Wei H., Zhang X., Zhao J. F., Wang Z. Y., Bickers D., Lebwohl M., Scavenging of hydrogen peroxide and inhibition of ultraviolet light- induced oxidative DNA damage by aqueous extracts from green and black teas. Free Radical Biology and Medicine 1999 26 11-12 1427 1435 2-s2.0-0033006410 10.1016/S0891-5849(99)00005-2
27. Fahey J. W., Talalay P., Antioxidant functions of sulforaphane: a potent inducer of phase II detoxication enzymes. Food and Chemical Toxicology 1999 37 9-10 973 979 2-s2.0-0032841203 10.1016/S0278-6915(99)00082-4
28. Lawenda B. D., Kelly K. M., Ladas E. J., Sagar S. M., Vickers A., Blumberg J. B., Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? Journal of the National Cancer Institute 2008 100 11 773 783 2-s2.0-44949179401 10.1093/jnci/djn148
29. Conklin K. A., Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integrative Cancer Therapies 2004 3 4 294 300 2-s2.0-9244261938 10.1177/1534735404270335
30. Berndtsson M., Hägg M., Panaretakis T., Havelka A. M., Shoshan M. C., Linder S., Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. International Journal of Cancer 2007 120 1 175 180 2-s2.0-33845465718 10.1002/ijc.22132